Pyridoxine, P2 Receptor Antagonism, and ATP-mediated Vasodilation in Young Adults

Summary

Previous research has identified adenosine triphosphate (ATP) as an important vasodilator that is released from red blood cells during exercise and exposure to hypoxic environments in adult humans. Further, older adults appear to have lower blood flow during both of these stressors and also have lower amounts of ATP released from their red blood cells. However, the contribution of ATP to vasodilation in response to exercise and hypoxia is currently unknown due to the lack of an effective ATP receptor antagonist. We aim to determine whether Vitamin B6 or its metabolite, Pyridoxal-5-Phosphate (PLP) is an effective ATP receptor antagonist.

Conditions

• Receptor Blockade

Interventions

DRUG

Adenosine Triphosphate

See arm/group descriptions

DRUG

Acetylcholine

See arm/group descriptions

DRUG

Sodium Nitroprusside

See arm/group descriptions

DRUG

Adenosine Diphosphate

See arm/group descriptions

DRUG

Adenosine Monophosphate

See arm/group descriptions

DRUG

Uridine Triphosphate

See arm/group descriptions

DRUG

Adenosine

See arm/group descriptions

DRUG

Vitamin B 6

See arm/group descriptions

DRUG

Pyridoxal 5'-Phosphate

See arm/group descriptions

Sponsors & Collaborators

• Colorado State University

  lead OTHER

Principal Investigators

• Frank Dinenno, PhD · Colorado State University

Study Design

Allocation

RANDOMIZED

Purpose

BASIC_SCIENCE

Masking

NONE

Model

PARALLEL

Eligibility

Min Age

18 Years

Max Age

30 Years

Sex

ALL

Healthy Volunteers

Yes

Timeline & Regulatory

Start

2019-02-07

Primary Completion

2021-06-01

Completion

2021-06-01

FDA Drug

Yes

Countries

• United States

Study Locations